Treatment of Middle East Respiratory Syndrome with a combination of lopinavir-ritonavir and interferon-β1b (MIRACLE trial): study protocol for a randomized controlled trial

Mohamed Hussein(Cairo University), Shmeylan Al Harbi(King Saud bin Abdulaziz University for Health Sciences), Fahad Al-Hameed, Jesna Jose(King Saud bin Abdulaziz University for Health Sciences), Yaseen M. Arabi(World Health Organization), Yusri Taha, Fatehi Elzein(Riyadh Armed Forces Hospital), Ahmad Deeb(King Saud bin Abdulaziz University for Health Sciences), Abdullah Almotairi(King Faisal Specialist Hospital & Research Centre), Ali Al Bshabshe(King Khalid University), Abdullah M. Assiri(King Khalid University), Frederick G. Hayden(University of Virginia Health System), Asim Alsaedi(King Saud bin Abdulaziz University for Health Sciences), Sarah Shalhoub(King Saud bin Abdulaziz University for Health Sciences), Hanan H. Balkhy(World Health Organization Regional Office for the Eastern Mediterranean), Ghaleb A. Almekhlafi(Riyadh Armed Forces Hospital), Yasser Mandourah(Riyadh Armed Forces Hospital), Nisreen Murad Sherbeeni(Riyadh Armed Forces Hospital), Robert Fowler(Sunnybrook Health Science Centre), Sameera Aljohani, Javed I. Memon(King Abdulaziz Hospital), Khalid Maghrabi(Alfaisal University), Abdulaziz Al‐Dawood, Adel Alothman(King Saud bin Abdulaziz University for Health Sciences), Ayman Kharaba(King Fahd Armed Forces Hospital), Majed Al Jeraisy(King Saud bin Abdulaziz University for Health Sciences), Ismael Qushmaq(King Faisal Specialist Hospital & Research Centre), Suleiman Kojan(King Saud bin Abdulaziz University for Health Sciences)

Trials

January 30, 2018

Cited by 261

|Intensive Care Medicine|2021|5.1k

|The Lancet|2020|3.7k

|Critical Care Medicine|2021|2.8k

|The Lancet. Gastroenterology & hepatology|2016|2k

|The Lancet Infectious Diseases|2020|1.8k

Related Papers